Provider review
StaveMD review
By The Dose Brief Desk · Updated
StaveMD separates a new-patient semaglutide offer from its ongoing price and names Red Rock Home Pharmacy.
Not rated. This review examines published program information; it is not a firsthand treatment review.
At a glance
- Semaglutide
- Injection $179 first four weeks for new patients, then $299/month; oral option $199
- Tirzepatide
- Injection from $249; full selected-plan terms need confirmation
- Availability
- State-dependent video requirements apply; confirm product eligibility.
- Treatment formats
- Semaglutide injections and oral option; tirzepatide injections.
Month-to-month language applies; a first-period discount is not the ongoing rate.
Separate the starter price from ongoing care
StaveMD advertises injectable semaglutide at $179 for a new patient’s first four weeks and $299 a month afterward. An oral semaglutide option is listed at $199, while injectable tirzepatide starts at $249. Those are separate formulations and offers, not one interchangeable price.
The oral option needs a formulation-specific discussion
A lower oral price is not evidence that it provides the same treatment as an injection or an approved branded tablet. Ask what is actually prescribed, why the clinician recommends it and how follow-up is arranged. Compare only after the formulation and usable supply are clear.
Clinical and pharmacy arrangements
StaveMD names Red Rock Home Pharmacy and links OpenLoop consent information. Its public process describes video visits where state rules require them. Confirm which clinician and pharmacy will handle your particular order rather than assuming every listed partner applies.
Cancellation and the current cycle
The site describes month-to-month care and a current-cycle refund provision if the visit has not occurred, while excluding prior-cycle refunds. Ask for the next processing deadline and what changes once medication is ordered. The new-patient discount should be evaluated alongside the next month’s bill.
What stands out
- Introductory and ongoing semaglutide rates are distinct
- Named pharmacy and clinical consent information
What to check
- Oral and injection offers need separate comparisons
- Refund timing depends on the care already provided
Sources and review scope
Public information checked in October 2026. Prices and eligibility can change. We have not enrolled in treatment, independently tested medications or verified the licenses of the clinicians and pharmacies involved in an individual prescription. Compounded medications are not FDA-approved; studies of approved brands do not establish that a compounded product has the same safety or effectiveness.